Status: Private

 

Avere Therapeutics is developing AVR-001, an oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) designed to deliver both convenience and competitive efficacy. IL-23 is one of the most validated targets in immunology, with clinical proof-of-concept data firmly established across psoriasis, ulcerative colitis, Crohn’s disease, and psoriatic arthritis. Multiple IL-23 inhibitors have been approved, demonstrating the potential safety of this treatment strategy.

 

To learn more, please visit: www.averetx.com